Understanding End-Stage Renal Disease on Dialysis ESRD on Dialysis and Chronic Kidney Disease Stage 5 on Dialysis requires accurate clinical documentation and medical coding. This resource provides information on diagnosis codes, healthcare guidelines, and best practices for documenting ESRD on dialysis for clinicians and medical coders. Learn about Chronic Kidney Disease Stage 5 on Dialysis management, treatment options, and the importance of precise medical coding for End-Stage Renal Disease on Dialysis patients.
Also known as
Chronic kidney disease stage 5
End-stage renal disease requiring dialysis or transplant.
Dependence on renal dialysis
Patient requires ongoing renal dialysis for survival.
Hypertensive chronic kidney disease with stage 5 chronic kidney disease
End-stage renal disease due to high blood pressure.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the patient receiving dialysis for ESRD?
When to use each related code
| Description |
|---|
| Kidney failure requiring dialysis |
| Chronic kidney disease stage 5 |
| Kidney failure with transplant |
Incorrect coding of the specific dialysis modality (hemodialysis vs. peritoneal) can lead to inaccurate reimbursement and quality reporting.
Insufficient documentation to support the diagnosis of ESRD, including underlying cause and dialysis dependence, poses an audit risk.
Missing documentation and coding of associated comorbidities like hypertension or diabetes can impact severity and reimbursement.
Q: What are the most effective strategies for managing fluid overload in patients with end-stage renal disease on dialysis (ESRD on dialysis)?
A: Fluid overload is a frequent complication in ESRD on dialysis patients and contributes significantly to morbidity and mortality. Effective management strategies include optimizing ultrafiltration during dialysis sessions, carefully monitoring interdialytic weight gain, restricting dietary sodium intake, and prescribing diuretics if residual renal function exists. Explore how incorporating bioimpedance spectroscopy can help assess fluid status more accurately and guide personalized ultrafiltration prescriptions. Consider implementing strategies to improve patient adherence to fluid restrictions, such as motivational interviewing and educational programs. Learn more about the impact of fluid overload on cardiovascular health in dialysis patients.
Q: How can I differentiate between mineral bone disease (MBD) and other bone disorders in patients with chronic kidney disease stage 5 on dialysis?
A: Differentiating mineral bone disease (MBD) from other bone disorders in chronic kidney disease stage 5 on dialysis patients can be challenging due to overlapping symptoms. Key distinguishing features of MBD in this population include abnormal levels of parathyroid hormone (PTH), calcium, and phosphorus, often accompanied by characteristic bone changes visible on imaging studies. Consider comparing bone biopsy findings with serum markers to confirm the diagnosis. Explore the role of newer bone turnover markers in assessing MBD activity. Learn more about the different types of renal osteodystrophy and their respective management approaches.
Patient presents with end-stage renal disease (ESRD) on dialysis, consistent with chronic kidney disease stage 5 requiring renal replacement therapy. The patient's renal failure necessitates hemodialysis treatments three times per week, as prescribed by the nephrologist. Uremic symptoms, including fatigue, nausea, and pruritus, are managed with medications and dietary restrictions. Laboratory results demonstrate elevated creatinine and blood urea nitrogen (BUN) levels, decreased glomerular filtration rate (GFR), and electrolyte imbalances requiring regular monitoring and adjustments to the dialysis prescription. The patient's arteriovenous fistula (AVF) is functioning well and is the primary access site for hemodialysis. Current treatment plan focuses on optimizing dialysis adequacy, managing fluid and electrolyte balance, controlling blood pressure, and addressing anemia with erythropoiesis-stimulating agents (ESAs). Patient education regarding medication adherence, dietary restrictions, and vascular access care is ongoing. Referral to a renal dietitian and social worker has been made for comprehensive ESRD management. Prognosis discussed with the patient, including the option of kidney transplantation if eligible. Follow-up scheduled with nephrology in two weeks to assess dialysis efficacy, monitor laboratory values, and address any emerging complications.